Drug Insights

Pimobendan: Detailed Review on its Transformative R&D Success, Mechanism of Action, and Drug Targets

30 August 2023
3 min read

Pimobendan's R&D Progress

Pimobendan is a small molecule drug that falls under the therapeutic area of cardiovascular diseases. It specifically targets cGMP-PDE, which is an enzyme involved in the regulation of cyclic guanosine monophosphate (cGMP) levels in the body. By inhibiting this enzyme, Pimobendan is able to increase the levels of cGMP, leading to vasodilation and positive inotropic effects.

According to the data provided by the Patsnap Synapse-Global Drug Intelligence Database,the active indication for Pimobendan is heart failure, a condition characterized by the heart's inability to pump blood effectively. This drug has been approved for use in the treatment of heart failure, making it a valuable option for patients suffering from this condition.

Pimobendan was originally developed by C.H. Boehringer Sohn AG & Co. KG, a pharmaceutical company known for its expertise in the field of biomedicine. The first approval of Pimobendan took place in January 1994 in Japan. There is no more additional approvals in other countries or regions based on the information provided by Synapse.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

A screenshot of a medical test

Description automatically generated

Mechanism of Action for Pimobendan: cGMP-PDE inhibitor

cGMP-PDE inhibitor is a type of drug that inhibits the enzyme phosphodiesterase (PDE) which specifically targets cyclic guanosine monophosphate (cGMP). This inhibitor prevents the breakdown of cGMP, leading to increased levels of cGMP in the body.

From a biomedical perspective, cGMP is an important signaling molecule involved in various physiological processes. It plays a crucial role in smooth muscle relaxation, vasodilation, and regulation of blood flow. By inhibiting the breakdown of cGMP, cGMP-PDE inhibitors promote the accumulation of cGMP, resulting in prolonged signaling and physiological effects.

In the context of biomedicine, cGMP-PDE inhibitors are commonly used to treat conditions such as erectile dysfunction, pulmonary arterial hypertension, and heart failure. By increasing cGMP levels, these inhibitors help relax smooth muscles, dilate blood vessels, and improve blood flow to specific areas of the body.

Drug Target R&D Development for Pimobendan

The drug target of Pimobendan is cGMP-PDE. According to PatSnap Synapse, as of 30 Aug 2023, there are a total of 44 cGMP-PDE drugs worldwide, from 57 organizations, covering 65 indications, and conducting 214 clinical trials.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by PatSnap Synapse, as of 30 Aug 2023, The drug types progressing most rapidly under the current target cGMP-PDE are Small molecule drugs and AAV-based gene therapy. Small molecule drugs have the highest number of approved drugs, with a total of 17. There is also one Small molecule drug in the Preclinical phase. Other drug types include Chemical drugs and Unknowns, which have limited representation.

Conclusion

In summary, Pimobendan is a small-molecule drug that targets cGMP-PDE and is used in the treatment of heart failure. It was developed by C.H. Boehringer Sohn AG & Co. KG and received its first approval in Japan in January 1994.

Exosomes and Tumor Immunotherapy
Advanced Tech.
6 min read
Exosomes and Tumor Immunotherapy
30 August 2023
Research on tumor immune evasion and tolerance mediated by exosomes has found that tumor cells can produce a large amount of exosomes.
Read →
Trehalose: Detailed Review on its Transformative R&D Success, Mechanism of Action, and Drug Targets
Drug Insights
4 min read
Trehalose: Detailed Review on its Transformative R&D Success, Mechanism of Action, and Drug Targets
30 August 2023
This article summarized the latest R&D progress of Trehalose, the Mechanism of Action for Trehalose, and the drug target for Trehalose.
Read →
An In-depth Analysis of Ropinirole's R&D Progress and Mechanism of Action on Drug Targets
Drug Insights
5 min read
An In-depth Analysis of Ropinirole's R&D Progress and Mechanism of Action on Drug Targets
30 August 2023
This article summarized the latest R&D progress of Ropinirole, Mechanism of Action for Ropinirole and drug target for Ropinirole.
Read →
Merck Initiates Phase 3 Clinical trial for PCSK9 Inhibitor MK-0616
Latest Hotspot
4 min read
Merck Initiates Phase 3 Clinical trial for PCSK9 Inhibitor MK-0616
29 August 2023
Merck has today made public the launch of the company's Phase 3 clinical trials, labeled as CORALreef, for MK-0616, a potential oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.